

Status: Currently Official on 14-Feb-2025
 Official Date: Official Prior to 2013
 Document Type: USP Monographs
 DocId: GUID-C2016B06-A563-4E2E-AABA-EF3F06B12F8D_2_en-US
 DOI: https://doi.org/10.31003/USPNF_M14117_02_01
 DOI Ref: fj91n

© 2025 USPC
 Do not distribute

Cefprozil for Oral Suspension

DEFINITION

Cefprozil for Oral Suspension is a dry mixture of Cefprozil and one or more suitable buffers, flavors, preservatives, suspending agents, and sweeteners. It contains NLT 90.0% and NMT 120.0% of the labeled amount of cefprozil ($C_{18}H_{19}N_3O_5S$).

IDENTIFICATION

• A. THIN-LAYER CHROMATOGRAPHY

Diluent: Acetone and 0.1 N hydrochloric acid (4:1)

Standard solution: 5 mg/mL of [USP Cefprozil \(Z\)-Isomer RS](#) in *Diluent*

Sample solution: Nominally 5 mg/mL of cefprozil in *Diluent* from Cefprozil for Oral Suspension. Shake for 5 min, and allow to settle. Use the supernatant.

Chromatographic system

(See [Chromatography \(621\)](#), [Thin-Layer Chromatography](#).)

Adsorbent: 0.25-mm layer of chromatographic silica gel mixture

Application volume: 10 µL

Developing solvent system: Butyl alcohol, glacial acetic acid, and water (60:20:20)

Analysis

Samples: *Standard solution* and *Sample solution*

Allow the spots to dry, and develop the chromatogram in an equilibrated chamber with the *Developing solvent system* until the solvent front has moved three-fourths of the length of the plate. Remove the plate, and allow it to air-dry in a hood. Place the dry plate in a chamber containing iodine vapors. Examine the plate, and locate the spots.

Acceptance criteria: The R_F value of the principal spot of the *Sample solution* corresponds to that of the *Standard solution*.

• **B.** The retention times of the cefprozil (Z)-isomer and cefprozil (E)-isomer peaks of the *Sample solution* correspond to those of *Standard solution 1* and *Standard solution 2*, respectively, as obtained in the Assay.

ASSAY

• PROCEDURE

Buffer: 11.5 g/L of monobasic ammonium phosphate in water. Adjust, if necessary, with phosphoric acid to a pH of 4.4.

Mobile phase: Acetonitrile and *Buffer* (100:900). [NOTE—Decreasing the proportion of acetonitrile increases retention times and improves the resolution between the cefprozil isomer peaks.]

Standard solution 1: 0.25 mg/mL of [USP Cefprozil \(Z\)-Isomer RS](#). Use this solution within 6 h.

Standard stock solution: 0.25 mg/mL of [USP Cefprozil \(E\)-Isomer RS](#)

Standard solution 2: 0.025 mg/mL of [USP Cefprozil \(E\)-Isomer RS](#) in water from the *Standard stock solution*. Use this solution within 6 h.

System suitability solution: A mixture of equal volumes of *Standard solution 1* and the *Standard stock solution*. Use this solution within 6 h.

Sample stock solution: Nominally 1 mg/mL of cefprozil in water from Cefprozil for Oral Suspension. Prepare as follows. Constitute one container of Cefprozil for Oral Suspension as directed in the labeling. Transfer a suitable aliquot, freshly mixed and free from air bubbles, to a volumetric flask, dilute with water to volume, and mix, sonicating briefly.

Sample solution: Nominally 0.3 mg/mL of cefprozil in water from the *Sample stock solution*. Pass a portion of this solution through a filter of 0.5-µm or finer pore size. Use this solution within 6 h.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 280 nm

Column: 3.9-mm × 25-cm; 5-µm packing L1

Flow rate: 1 mL/min

Injection volume: 10 µL

System suitability

Samples: *Standard solution 1* and *System suitability solution*

[NOTE—The relative retention times for the cefprozil (Z)-isomer and the cefprozil (E)-isomer are about 0.7 and 1.0, respectively.]

Suitability requirements

Resolution: NLT 2.5 between cefprozil (Z)-isomer and cefprozil (E)-isomer, *System suitability solution*

Column efficiency: NLT 2500 theoretical plates, cefprozil (Z)-isomer, *Standard solution 1*

Calculate as follows:

$$\text{Result} = (t_R / W_{h/2})^2 \times 5.545$$

t_R = retention time of cefprozil (Z)-isomer

$W_{h/2}$ = peak width at half-height

Tailing factor: 0.9–1.1, cefprozil (Z)-isomer, *Standard solution 1*

Calculate as follows:

$$\text{Result} = W_{0.1} / 2f$$

$W_{0.1}$ = width of the peak at 10% height

f = distance from the peak maximum to the leading edge of the peak measured at 10% of the peak height

Relative standard deviation: NMT 2.0%, *Standard solution 1*

Analysis

Samples: *Standard solution 1*, *Standard solution 2*, and *Sample solution*

Calculate the concentration, in mg/mL, of the cefprozil (Z)-isomer in the *Sample solution*:

$$\text{Result} = (r_U / r_S) \times C_S \times P \times F$$

r_U = peak response of the cefprozil (Z)-isomer from the *Sample solution*

r_S = peak response of the cefprozil (Z)-isomer from *Standard solution 1*

C_S = concentration of [USP Cefprozil \(Z\)-Isomer RS](#) in *Standard solution 1* (mg/mL)

P = potency of the cefprozil (Z)-isomer in [USP Cefprozil \(Z\)-Isomer RS](#) (µg/mg)

F = correction factor, 0.001 mg/µg

Calculate the concentration, in mg/mL, of the cefprozil (E)-isomer in the *Sample solution*:

$$\text{Result} = (r_U / r_S) \times C_S \times P \times F$$

r_U = peak response of the cefprozil (E)-isomer from the *Sample solution*

r_S = peak response of the cefprozil (E)-isomer from *Standard solution 2*

C_S = concentration of [USP Cefprozil \(E\)-Isomer RS](#) in *Standard solution 2* (mg/mL)

P = potency of the cefprozil (E)-isomer in [USP Cefprozil \(E\)-Isomer RS](#) (µg/mg)

F = correction factor, 0.001 mg/µg

Calculate the percentage of the labeled amount of cefprozil ($C_{18}H_{19}N_3O_5S$) in the portion of Cefprozil for Oral Suspension taken:

$$\text{Result} = [(C_Z + C_E) / C_U] \times 100$$

C_Z = concentration of the cefprozil (Z)-isomer in the *Sample solution* (mg/mL)

C_E = concentration of the cefprozil (E)-isomer in the *Sample solution* (mg/mL)

C_U = nominal concentration of cefprozil in the *Sample solution* (mg/mL)

Acceptance criteria: 90%–120.0%

PERFORMANCE TESTS

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#)

For solids packaged in single-unit containers: Meets the requirements

- [DELIVERABLE VOLUME \(698\)](#)

For solids packaged in multiple-unit containers: Meets the requirements

SPECIFIC TESTS

- [pH \(791\)](#)

Sample solution: Constitute Cefprozil for Oral Suspension as directed in the labeling.

Acceptance criteria: 4.0–6.0

- [WATER DETERMINATION, Method I \(921\)](#): NMT 3.0%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers.
- **USP REFERENCE STANDARDS (11).**
[USP Cefprozil \(E\)-Isomer RS](#)
[USP Cefprozil \(Z\)-Isomer RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
CEFPROZIL FOR ORAL SUSPENSION	Documentary Standards Support	SM12020 Small Molecules 1

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 45(6)

Current DocID: GUID-C2016B06-A563-4E2E-AABA-EF3F06B12F8D_2_en-US

Previous DocID: GUID-C2016B06-A563-4E2E-AABA-EF3F06B12F8D_1_en-US

DOI: https://doi.org/10.31003/USPNE_M14117_02_01

DOI ref: [fj91n](#)

OFFICIAL